



Name	Stephen Lam CHAN
Affiliation	The Chinese University of Hong Kong
Country	Hong Kong SAR
Major Field	Oncology

Educational Background	
2018	Medical Doctor (MD), The Chinese University of Hong Kong
2016	Fellowship of Royal College of Physician (London)
2014	Fellowship of Royal College of Physician (Edinburgh)
2007	Fellow of Hong Kong Academy of Medicine, FHKAM (Medicine)
2007	Fellow of Hong Kong College of Physician, FHKCP (Medical Oncology)
2003	Member of Royal College of Physicians, MRCP (UK)
2000	Bachelor of Medicine and Bachelor of Surgery (MBBS), HKU

Professional Experience	
Position:	
01/2026 – Present	President, International Liver Cancer Association (ILCA)
11/2021– Present	Ip’s Family Trust Professor of Clinical Oncology, The Chinese University of Hong Kong
10/2021– Present	Assistant Dean (Health Systems), Faculty of Medicine, The Chinese University of Hong Kong
08/2021 – Present	Professor (Clinical), Department of Clinical Oncology, Faculty of Medicine, The Chinese University of Hong Kong
03/2014 – 07/2021	Associate (Clinical) Professor, Department of Clinical Oncology, Faculty of Medicine, The Chinese University of Hong Kong
03/2008 – 02/2014	Assistant (Clinical) Professor, Department of Clinical Oncology, Faculty of Medicine, The Chinese University of Hong Kong
07/2007 – 03/2008	Specialist, Department of Clinical Oncology, Prince of Wales Hospital
07/2001 – 06/2007	Resident, Department Clinical Oncology, Prince of Wales Hospital



Main Scientific Publications

Recent Relevant Publications:

1. **Chan, S.L.**, Sun, H.C., Xu, Y., Zeng, H.M., El-Serag, H.B., Lee, J.M., Schwartz, M., Finn, R., Seong, J., Wang, X.W., Paradis, V., Abou-Alfa, G.K., Rimassa, L., Kao, J.H., Zhang, B.H., Llovet, J.M., Bruix, J., Yip, T.C.F., Wong, V.W.S., Wong, G.L.H., Chan, L.L., Liu, M.Q., Gao, Q., Shen, F., Kelley, R.K., Cheng, A.L., Kurosaki, M., Toyoda, H., Cheng, W.X., Murakami, T., Liang, P., Zucman-Rossi, J., Minami, Y., Miyayama, S., Wang, K., Man, K., Hasegawa, K., Li, Q., Tsuchiya, K., Xu, L., Chew, V., Chow, P., Hosida, Y., Lujambio, A., Ng, I.O.L., Sakamoto, M., Park, Y.N., Yau, T., Kudo, M., Fan, J., Zhou J. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. *Lancet*. 2025 published online July 28 2025. doi: 10.1016/S0140-6736(25)01042-6 (Impact factor: 88.5)
2. Sangro, B., Kudo, M., Erinjeri, J.P., Qin, S., Ren, Z., **Chan, S.L.**, Arai, Y., Heo, J., Mai, A., Escobar, J., Lopez Chuken, Y.A., Yoon, J.H., Tak, W.Y., Breder, V.V., Suttichaimongkol, T., Bouattour, M., Lin, S.M., Peron, J.M., Nguyen, Q.T., Yan, L., Chiu, C.F., Santos, F.A., Veluvolu, A., Thungappa, S.C., Matos, M., Zotkiewicz, M., Udoe, S.I., Kurland, J.F., Cohen, G.J., Lencioni, R.; EMERALD-1 Investigators. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. *Lancet*. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. PMID: 39798579. (Impact factor: 88.5)
3. Chan, L.L., Wong, V.W.S., **Chan, S.L.** A New Predictive Algorithm toward Risk-Based Surveillance for Liver Cancer. *NEJM Evid*. 2024 Nov;3(11):EVIDe2400344. doi: 10.1056/EVIDe2400344. PMID: 39437134. (Impact factor: 78.5)
4. Vogel, A., **Chan, S.L.**, Dawson, L.A., Kelley, R.K., Llovet, J.M., Meyer, T., Ricke, J., Rimassa, L., Sapisochin, G., Vilgrain, V., Zucman-Rossi, J., Ducreux, M., ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*. 2025 May;36(5):491-506. doi: 10.1016/j.annonc.2025.02.006. PMID: 39986353. (Impact factor: 65.4)
5. Yan, B.P., Kam, K.K., Lai, A., Ng, C.L., Chan, N.Y., Chan, L.S., Wong, C.W., Yam, P.W., Chi, W.K., **Chan, S.L.**, Wong, R.H.L., Wu, E.B., Chan, J.Y., Lee, A.P., Tan, G.M. Balloon pericardiectomy for malignant pericardial effusion: the PMAP trial. *Eur Heart J*. 2025 Jul 30;ehaf516. doi: 10.1093/eurheartj/ehaf516. Epub ahead of print. PMID: 40737211. (Impact factor: 35.6)
6. **Chan, S.L.**, Lamarca, A., Hsu, C., Moreno, V., Chan, L.L., Keenan, B.P. New targets and new drugs for hepatobiliary cancers. *J Hepatology*. 2025, accepted. (Impact factor: 33.0)
7. **Chan, S.L.**, Ryoo, B.Y., Mo, F., Chan, L.L., Cheong, J., Li, L., Wong, K.H., Kim, N., Yoo, C. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment. *J Hepatology*. 2024; S0168-8278(24)00216-2. doi: 10.1016/j.jhep.2024.03.033. (Impact factor: 33.0)
8. Chan, L.L., Chan, A.W.H., Yip, T.C.F., Wong, G.L.H., Ngai, A.K.H., Mo, F., Chok, S.H., Kung, J.W.C., Chu, C.M., Mok, K., Li, M.S.C., Wong, V.W.S., **Chan, S.L.** Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era. *J Hepatol*. 2025 Jun 9;S0168-8278(25)02266-4. doi: 10.1016/j.jhep.2025.05.028. PMID: 40499818. (Impact factor: 33.0)
9. Long, X., Kwong, T.T., Cheng, A.S., **Chan, S.L.** Targeting tumour endothelial cells in liver cancer: The end of beginning. *J Hepatol*. 2025 Apr;82(4):553-555. doi: 10.1016/j.jhep.2024.12.032. PMID: 39725355. (Impact factor: 33.0)



Main Scientific Publications

10. Lau, G., Abou-Alfa, G.K., Cheng, A.L., Sukeepaisarnjaroen, W., Dao, T.V., Kang, Y.K., Thungappa, S.C., Kudo, M., Sangro, B., Kelley, R.K., Furuse, J., Park, J.W., Sunpaweravong, P., Fasolo, A., Yau, T., Kawaoka, T., Azevedo, S., Reig, M., Assenat, E., Yarchoan, M., He, A.R., Makowsky, M., Gupta, C., Negro, A., **Chan, S.L.** Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. *J Hepatol.* 2025 Feb;82(2):258-267. doi: 10.1016/j.jhep.2024.07.017. PMID: 39089633. (Impact factor: 33.0)
11. Lau, G., Abou-Alfa, G.K., **Chan, S.L.** Reply to: "STRIDE's efficacy and safety in Asian hepatocellular carcinoma". *J Hepatol.* 2025 Jun;82(6):e346-e347. doi: 10.1016/j.jhep.2025.02.037. PMID: 40024547. (Impact factor: 33.0)
12. Rimassa, L., **Chan, S.L.**, Sangro, B., Lau, G., Kudo, M., Reig, M., Breder, V., Ryu, M.H., Ostapenko, Y., Sukeepaisarnjaroen, W., Varela, M., Tougeron, D., Crysler, O.V., Bouattour, M., Van Dao, T., Tam, V.C., Faccio, A., Furuse, J., Jeng, L.B., Kang, Y.K., Kelley, R.K., Paskow, M.J., Ran, D., Xynos, I., Kurland, J.F., Negro, A., Abou-Alfa, G.K. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. *J Hepatol.* 2025 Apr 11:S0168-8278(25)00226-0. doi: 10.1016/j.jhep.2025.03.033. PMID: 40222621. (Impact factor: 33.0)
13. Yoo, C., Ueno, M., Klümpen, H.J., Kelley, R.K., Vogel, A., Furuse, J., Ren, Z., Yau, T., **Chan, S.L.**, Ozaka, M., Oh, S.C., Gu, S., Park, J.O., Valle, J.W., Edeline, J., Kim, J.G., Kamble, S., Norquist, J.M., Yu, L., Malhotra, U., Finn, R.S. Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study. *J Hepatol.* 2025 Mar 26: S0168-8278(25)00207-7. doi: 10.1016/j.jhep.2025.03.019. PMID: 40154623. (Impact factor: 33.0)
14. Tu, Y., Wu, H., Zhong, C., Liu, Y., Xiong, Z., Chen, S., Wang, J., Wong, P.P., Yang, W., Liang, Z., Lu, J., Chen, S., Zhang, L., Feng, Y., Si-Tou, W.W., Yin, B., Lin, Y., Liang, J., Liang, L., Vong, J.S.L., Ren, W., Kwong, T.T., Leung, H., To, K.F., Ma, S., Tong, M., Sun, H., Xia, Q., Zhou, J., Kerr, D., La Thangue, N., Sung, J.J.Y., **Chan, S.L.**, Cheng, A.S. Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma. *Gut.* 2025 Mar 6;74(4):613-627. doi: 10.1136/gutjnl-2024-332281. PMID: 39486886; PMCID: PMC12013592. (Impact factor: 25.8)
15. Kang, W., Huang, C., Yan, V.K.C., Wei, Y., Shami, J.J.P., Li, S.T.H., Yang, Y., Ye, X., Tang, J., Lee, S.F., Lee, V.H.F., **Chan, S.L.**, El Helali, A., Lam, K.O., Ngan, R.K.C., Wong, I.C.K., Chan, E.W. Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in cancer-associated venous thrombosis. *Nat Commun.* 2024 Jul 5;15(1):5657. doi: 10.1038/s41467-024-50037-1. PMID: 38969649; PMCID: PMC11229502. (Impact factor: 15.7)
16. Kim, G.A., Lim, Y.S., Han, S., Choi, G.H., Choi, W.M., Choi, J., Sinn, D.H., Paik, Y.H., Lee, J.H., Lee, Y.B., Cho, J.Y., Heo, N.Y., Yuen, M.F., Wong, V.W., **Chan, S.L.**, Yang, H.I., Chen, C.J. Viral Load-Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B : A Multinational Study for the Development and External Validation of a New Prognostic Model. *Ann Intern Med.* 2024 Oct;177(10):1308-1318. doi: 10.7326/M24-0384. PMID: 39284185. (Impact factor: 15.2)
17. Kwong, T.T., Xiong, Z., Zhang, Y., Wu, H., Cao, J., Wong, P.P.C., Liu, X., Wang, J., Wong, C.H., Tse, G.M.K., Sung, J.J.Y., Zhou, J., Cheng, A.S.L., **Chan, S.L.** Overcoming immunotherapy resistance in hepatocellular carcinoma by targeting myeloid IL-8/CXCR2 signaling. *Mol Ther.* 2025 Apr 2;33(4):1659-1673. doi: 10.1016/j.ymthe.2025.02.002. PMID: 39916327; PMCID: PMC11997504. (Impact factor: 12.0)
18. Ma, M.L., Zhang, W.Z., Jiang, P., Ji, L., Xiong, D., Peng, W., Lam, W.K.J., Yu, S.C.Y., Choy, L.Y.L., Tse, R.T., Cheng, S.H., Zhou, Q., Bai, J., Hu, X., Shi, Y., Chan, L.L., Chan, W.T.C., Wong, P.Y., Fung, S., Lau, S.L., Wong, J., **Chan, S.L.**, Chiu, P.K.F., Teoh, J.Y.C., Poon, L.C., Ng, C.F., Szeto, C.C., Chan, K.C.A., Lo, Y.M.D. Chromatin accessibility states affect transrenal clearance of plasma DNA: Implications for urine-based diagnostics. *Med.* 2025 Apr 4:100646. doi: 10.1016/j.medj.2025.100646. PMID: 40209704. (Impact factor: 11.8)